The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
From their LinkedIn page just now:
Yourgene Health are proud to be supporting #Novacyt #NCYT with the manufacture of #Covid19 PCR tests https://bit.ly/2Jg0ZsQ
Molecular test:
A molecular for active infections. It detects the virus’ genetic material from a swab of the patients nose or throat.
Antibody test
From a blood sample, to detect that a person has already had the virus. The test detects the body’s immune response to the infection. Antibodies can usually be detected from about. Day 5 of an infection.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, today announces that, due to the timing of the General Meeting and completion of the proposed Admission of both the Placing Shares and Subscription Shares on 23 April 2020, it will now announce its financial results for the 17 months ended 31 December 2019 on Wednesday, 6 May 2020.
The analyst briefing due to be held on Tuesday, 21 April 2020 will now be held by Alastair Smith, Chief Executive Officer, and Tony Gardiner, Chief Financial Officer, by webcast presentation, followed by a Q&A session at 09.30 hrs on Wednesday, 6 May 2020. Pre-registration is required for attendance to the call. To confirm attendance, please email avacta@yellowjerseypr.com and you will be sent the link to join.
The shareholder and investor meeting that was due to be held on Wednesday, 22 April 2020 will now take place as a webcast presentation, followed by a Q&A session, at 17.00 hrs on Wednesday, 6 May 2020. You can register and access the shareholder and investor webcast via the following link:
https://webcasting.brrmedia.co.uk/broadcast/5e985bc231da814c9fc6a477.
Alastair Smith, Chief Executive Officer, and Tony Gardiner, Chief Financial Officer, will host the call and look forward to responding to questions from existing and prospective investors.
Synairgen plc
('Synairgen' or the 'Company')
Result of General Meeting
Southampton, UK - 14 April 2020: Synairgen (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the passing of the Resolutions at the General Meeting held earlier today. The Conditional Placing and Subscription remain conditional on Admission of the relevant New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Wednesday 15 April 2020.
As announced on 31 March 2020, the first patient was dosed in the Company's double-blind, placebo-controlled trial of SNG001 (the Company's wholly-owned inhaled formulation of interferon-beta-1a) in COVID-19 patients. The trial has now been labelled as an Urgent Public Health study by the National Institute for Health Research (NIHR). Further updates will be made in due course.
With effect from Admission, the Company will have 149,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
I also dialled in, and in addition to points arrests made, he was asked about capacity and planning and he said that the company is planning for and has capacity for future growth 6-9 months out and again that forward planning has been driven by the collect experience of the management team.
Yourgene Health’s Chief Operating Officer will be discussing the Company’s response to the #Covid19 #Coronavirus crisis tomorrow, Tuesday 7th April at 4pm BST. Register here for the #BruntwoodSciTech Webinar – Adapting During Crisis
https://lnkd.in/g5M9qpH
From Sky newsHealth specialists have said they are currently "testing to the limit of our materials", adding that they are ready to increase capacity, but only if given a "reliable supply" of equipment to do so.The Institute of Biomedical Science (IBMS) warned there is a "very real risk" that hospitals may run out of reagents, leaving patients unable to be tested.A reagent is a chemical needed to determine if a coronavirus test is positive or negative."The UK has numerous high-quality accredited laboratories with suitable equipment, with the capability to process over 100,000 tests per day, set up and ready to meet testing targets," a spokesman for the IBMS said."Currently, England could process up to 25,000 a day, which by May could rise to 100,000, meeting the ambitious target set down by Matt Han****, all within the NHS. However, there is a material supply issue with a worldwide shortage in reagent kits."The supply of precision plastics that are used with the reagents are not due to be ready until mid-May."
How big is our market share in Italy, as there’s going to be a lot of pregnancies there over the coming months..